Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis
1
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
Arialys TherapeuticsART5803
Arialys TherapeuticsART5803
Arialys TherapeuticsART5803
Clinical Trials (3)
Total enrollment: 101 patients across 3 trials
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Start: May 2026Est. completion: May 202830 patients
Phase 2Not Yet Recruiting
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
Start: Feb 2025Est. completion: Aug 20257 patients
Phase 1Completed
Phase 1 Study of ART5803 in Healthy Participants
Start: Sep 2024Est. completion: Oct 202564 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.